<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1472-6963-3-7.anc" start="4784" end="4788" sStart="-1" offset="0" sid="null" wn="2" wnkey="work%1:06:00::" text="Building on our previously published &lt;b&gt;work&lt;/b&gt; on the Canadian costs of major macrovascular complications of diabetes [ 12 ] , the aim of this paper is to provide key pieces of that complex economic puzzle." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="31047" end="31051" sStart="null" offset="185" sid="r11.true.j.0941" wn="1" wnkey="true%3:00:00::" text="As noted earlier, it is not uncommon to find US or European costs for diabetes used as a proxy for Canadian costs, even in official reports [ 6 ] ; however, the true relevance of these costs to a Canadian population can only be assumed." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="24299" end="24310" sStart="null" offset="118" sid="r11.recommend.v.0505" wn="1" wnkey="recommend%2:32:01::" text="There is no state cost as beyond the initial diagnostic tests, there is no further management recommended." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="20809" end="20818" sStart="null" offset="284" sid="r11.recommend.v.0504" wn="1" wnkey="recommend%2:32:01::" text="The Canadian clinical practice recommendations of 1998 recognize that some patients with type 2 diabetes who have proteinuria may benefit from this type of therapy [ 27 ] and suggest that ACE Inhibitors should be considered, but do not recommend them for all patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="30090" end="30100" sStart="null" offset="194" sid="r10.particular.j.0819" wn="2147483647" wnkey="null" text="Yet, given the size of the problem, the acknowledged concern and initiatives undertaken to address diabetes on a national level and for the native Canadian population in particular, it is surprising that there is so little available Canadian information about the cost of the complications of diabetes, particularly at a level detailed enough to be meaningful to decision makers or those doing economic analyses." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="4901" end="4906" sStart="null" offset="162" sid="r9.paper.n.0377" wn="5" wnkey="paper%1:10:02::" text="Building on our previously published work on the Canadian costs of major macrovascular complications of diabetes [ 12 ] , the aim of this paper is to provide key pieces of that complex economic puzzle." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="9277" end="9282" sStart="null" offset="124" sid="r9.paper.n.0943" wn="2" wnkey="paper%1:10:01::" text="Additional references used for specific complications are noted within the appropriate sections of this paper." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="30385" end="30390" sStart="null" offset="20" sid="r9.paper.n.0800" wn="5" wnkey="paper%1:10:02::" text="The purpose of this paper is to provide comprehensive cost estimates for several common complications of diabetes in a manner that can be useful to interested parties." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="32097" end="32102" sStart="null" offset="217" sid="r9.level.n.0641" wn="1" wnkey="level%1:07:00::" text="Although there may be clinical consensus on the management of a condition, type and availability of health care services, medical practice patterns, and access to care will affect the type and level of care actually delivered." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="30257" end="30262" sStart="null" offset="361" sid="r9.level.n.0752" wn="1" wnkey="level%1:07:00::" text="Yet, given the size of the problem, the acknowledged concern and initiatives undertaken to address diabetes on a national level and for the native Canadian population in particular, it is surprising that there is so little available Canadian information about the cost of the complications of diabetes, particularly at a level detailed enough to be meaningful to decision makers or those doing economic analyses." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="26357" end="26362" sStart="null" offset="500" sid="r9.level.n.0412" wn="2" wnkey="level%1:26:01::" text="Information regarding post-acute care dispositions, rehabilitation, readmissions for debridement and major stump revisions, and use of prosthetic devises and durable medical equipment were obtained from the OCCP database, provider surveys and publications [ 77 78 79 ] . The increase in event cost from first ($24,583) to second ($26,077) represents a shift to a higher anatomical, and thus, more costly level of amputation for the second amputation as noted in the Rochester study [ 76 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="32616" end="32620" sStart="null" offset="50" sid="r7.1.face.n.0563" wn="2147483646" wnkey="null" text="We would argue &quot;no&quot; even in the face of the cautionary words provided above." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="16601" end="16608" sStart="null" offset="7" sid="r11.absence.n.0244" wn="1" wnkey="absence%1:26:00::" text="In the absence of Canadian-specific data, the ratio of 3 stable to 1 unstable patient with angina [ 61 ] , and the 96% proportion of unstable patients treated as inpatients were obtained from the literature [ 62 ] . OCCP data revealed that of those admitted with angina, 28% were transported by ambulance." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="31838" end="31845" sStart="null" offset="323" sid="r11.absence.n.0018" wn="1" wnkey="absence%1:26:00::" text="As the state cost is applied to every year the patient is in that health state, a substantial miscalculation of the lifetime cost attributed to stroke would have been produced, even though it would have been based on the best available data and accepted as a reasonable proxy in the absence of Canadian data." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6963-3-7.anc" start="31838" end="31845" sStart="null" offset="323" sid="r11.absence.n.0018" wn="1" wnkey="absence%1:26:00::" text="As the state cost is applied to every year the patient is in that health state, a substantial miscalculation of the lifetime cost attributed to stroke would have been produced, even though it would have been based on the best available data and accepted as a reasonable proxy in the absence of Canadian data." />
  </sentences>
</list>